About Monopar therapeutics inc.

About company

Monopar Therapeutics is an emerging biopharmaceutical company focused on developing orphan oncology compounds. Its lead compound, Hu-ATN-658, is a novel monoclonal antibody for the potential treatment of several deadly cancers. Hu-ATN-658 targets the urokinase plasminogen activator receptor (uPAR). Cancer Research UK will be conducting Hu-ATN-658’s early development, including a Phase I clinical trial. In 2014, Chandler D. Robinson, Christopher M. Starr, and Andrew P. Mazar founded the company in Wilmette, Illinois.